Blog

A new article in Nature microbiology by Wohlfahrt et al. describes "L-form conversion in Gram-positive bacteria enables escape from phage infection" Abstract: At the end of a lytic bacteriophage replication…

Hope that bacteriophages could represent a new therapeutic strategy for resistant bacterial infections has been bolstered by a study conducted by BiomX in cystic fibrosis (CF) patients. While still early,…

Phage Therapy in Germany—Update 2023 by Willy et al. Viruses 2023, 15(2), 588; https://doi.org/10.3390/v15020588 Abstract Bacteriophage therapy holds promise in addressing the antibiotic-resistance crisis, globally and in Germany. Here, we provide an overview…

A new article punished in the International Journal of Pharmaceutics describes the "Bacteriophage endolysin powders for inhaled delivery against pulmonary infections" by Wang et al. https://doi.org/10.1016/j.ijpharm.2023.122679 Abstract Endolysins are bacteriophage-encoded…

The 6th World Congress on Targeting Phage Therapy 2023 will take place on June 1-2 at IRIS, Paris, France.  Targeting Phage 2023: Questions, Controversies, and What is Next? Targeting Phage…

A regulatory pathway needs to be developed if the UK is to reap the benefits of bacteriophage therapy, Applied Microbiology International (AMI) has warned. France, Belgium and Poland are already…

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Microbiology". Deadline for manuscript submissions: 12 May 2023 Special Issue "Bacteriophages: Infection, Genetics and Therapy" https://www.mdpi.com/journal/life/special_issues/196IPXRO2G Dear Colleagues, Bacteriophages…

Title: "The dynamic interplay of bacteriophage, bacteria and the mammalian host during phage therapy" AbstractFor decades, biomedically-centered studies of bacteria have focused on mechanistic drivers of disease in their mammalian…

In this fantastic work, Chan and colleagues show that using phage to treat P. aeruginosa lung infections in people with cystic fibrosis can lower P. aeruginosa levels, improve lung function, and drive…

Vésale Bioscience, a research and development company of solutions and treatments using phage therapy for multi-resistant infections, has announced it has received €1.8m (£1.6m) in grants from the European Innovation Council…